----

----

**LICENSE      AND SUPPLY AGREEMENT**

**THIS      AGREEMENT**

*** ***

**                     RECITALS:**

|   | **SECTION                1 - DEFINITIONS** |
|--------|--------------------------------------------|

| 1.1 | In                this Agreement, unless the context otherwise                requires: |
|-----|-----------------------------------------------------------------------------------------|

----

----

----

** **

----

----

----

|   | (a) | customs                duties, sales or use taxes, or other taxes (excluding income or                corporation tax), directly related to the sale of Product which are                paid                by Ascend or its sub-licensees, as the case may                be; |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | a                discount from the gross sales proceeds to cover such normal costs                as are                incurred by Ascend  or its sub-licensees, as the case may be, in                respect of transport, shipping, and insurance, to the extent specifically                referenced in the invoice and included in the invoice                price; |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | customary                trade, quantity and cash discounts, chargebacks, deductions, and                rebates                directly related to the sale of Product and actually allowed and                taken; |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | amounts                repaid or credited by reasons of rejections or return of goods, or                because                of retroactive price reductions specifically identifiable to the                Product;                and |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

| (e)                   | amounts                payable resulting from governmental (or agency thereof) mandated                rebate                programs and other third-party rebates to the extent actually                allowed. |
|---------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |  “Product”                means the 4% w/w progesterone gel (45 mg) in single use, one piece,                disposable vaginal applicators containing 1.45 g of gel and delivering                1.125 g of gel, utilizing the Columbia Technology, and approved by                the FDA                under NDA 20-701. |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

**SECTION      2 – LICENSE**

**License**

|  |  2.1.1 | Columbia                hereby grants to Ascend an exclusive license (even as to Columbia)                in the                Territory under the Columbia Technology to the extent it relates                exclusively to the Product, and not to any other product or active                component, to import, market, promote, use, distribute, offer to                sell, and                sell the Product in the Territory, but for the avoidance of doubt                no                rights are granted hereunder for Ascend to manufacture the                Product. |
|--|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |  2.1.2 | Columbia                hereby grants to Ascend a non-exclusive license under Columbia Technology                that is not associated exclusively with the Product but that, in                the                absence of the license provided in this Section 2.1.2, would                necessarily be infringed by Ascend's practice of the license granted                in                Section 2.1.1.  This non-exclusive license shall apply only to                the extent necessary for Ascend to exercise its rights and discharge                its                obligations under this Agreement with respect to the                Product. |
|--------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |  2.1.3 | Ascend                shall have the right to grant sublicenses under the rights and licenses                granted to it in this Article 2, provided that, any such sublicense                shall be approved by Columbia, said approval not being unreasonably                withheld, conditioned or delayed, and shall obligate the sublicensee                to                comply with all relevant terms of this Agreement and Ascend remains                liable                to Columbia for all material acts and omissions of any such                sublicensee. |
|--------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |  2.1.4 | Except                as specifically set forth in this Agreement, neither Party shall                acquire                any license or other intellectual property interest, by implication                or                otherwise, in any |
|--------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

|   |  information                disclosed to it under this Agreement or under any patents or patent                applications owned or controlled by the other Party or its                Affiliates. |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.2 |   | Except                as otherwise expressly provided herein, nothing in this Agreement                shall,                during or after the Term hereof, grant Ascend any of Columbia’s rights in                or related to the Product, including, but not limited to, Columbia’s                rights in or to trademarks, copyrights, the Product’s NDA, Drug Master                Files, patent or other intellectual property rights, preclinical                or                clinical data, manufacturing rights relating to the Product, or any                supply                of the Product or the active ingredient thereof.  For the                avoidance of doubt, no rights are granted to Ascend hereunder with                respect                to the Product or the manufacture, use, promotion, marketing or sale                thereof outside the Territory. |
|-----|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| SECTION                3 - INTELLECTUAL PROPERTY |  |
|--------------------------------------------------|--|

| 3.1 | **Ownership                of Intellectual                Property** |
|-----|----------------------------------------------------------------------|

|   |  3.1.1 | Columbia                shall remain the sole owner of all Columbia                Technology. |
|--------|-------------|------------------------------------------------------------------------------------------------|

|   |  3.1.2 | Columbia                shall be entitled to use the Columbia Technology in connection with                Columbia’s commercial arrangements otherwise than in relation to the                Product in the Territory, and in connection with the Product following                termination of this Agreement. |
|--------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.2 | Each                Party shall promptly notify the other if it becomes aware of any                claim or                threatened or likely claim that the Product or the development,                manufacture, importation, marketing, use or sale thereof infringes                a                patent or other intellectual property right of any third                party.  In the event of such an infringement claim or potential                claim, the Parties shall discuss in good faith the actions, if any,                to be                taken; provided that in no event shall either Party be obligated                to                continue manufacture, importing, marketing, sale and distribution                of the                Product if it reasonably believes that such action would constitute                infringement of a third party's intellectual property                rights. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.3 | **Enforcement** |
|-----|-----------------|

|   | 3.3.1     | Ascend                and Columbia shall promptly inform the other in writing of any alleged                infringement of which it shall become aware by a third party of any                patents within the Columbia Technology and Ascend shall provide Columbia                with any available evidence of                infringement. |
|--------|-------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3.3.2     | Columbia,                at its option, shall be entitled to institute or have instituted                any                administrative, judicial or other proceeding ("Enforcement Proceedings")                to prevent or stop any infringement or unauthorized use of the Columbia                Technology at its own expense and for its own benefit. Ascend agrees                to                provide all reasonable co-operation and assistance to Columbia in                relation                to any such Enforcement Proceedings and agrees to be named as a party                in                any Enforcement |
|--------|-------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

|   | 3.3.3     | In                the event that Columbia does not institute or have instituted Enforcement                Proceedings relating to Columbia Patents, then Ascend may enforce                such                rights at its own expense.  Columbia shall cooperate with Ascend                and provide all reasonable assistance in relation to any such Enforcement                Proceedings** **and agrees to be named as a party in any                Enforcement Proceedings, as necessary, instituted by Ascend                hereunder.  Ascend  shall seek written approval from                Columbia, which may not be unreasonably withheld or delayed, prior                to                taking action and shall keep Columbia informed of the action and                may not                enter into any settlement agreement without Columbia’s consent, which may                not be unreasonably withheld or delayed.  Any reasonable fees                and costs borne by Columbia shall be reimbursed by Ascend.  In                the event that Ascend decides to enforce the Columbia Patents in                accordance with this paragraph, any recovery remaining after the                deduction                of reasonable expenses (including attorneys' fees and expenses) incurred                in relation to such Enforcement Proceedings shall** **be                shared equally between the Parties. |
|--------|-------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.4 | **Defense** |
|-----|-------------|

|   | 3.4.1     | In                the event that a claim or proceeding is threatened or brought against                a                Party by a third party alleging that the manufacture, sale, use or                offer                for sale of Product infringes the patent or other intellectual property                rights of that or any other third party in the Territory (“IP Claim”),                that Party shall promptly advise the other Party of such IP Claim                and the                Parties shall meet to discuss the manner in which such IP Claim should                be                defended. |
|--------|-------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3.4.2     | Neither                Party shall acknowledge to the third party or to any other person                the                validity of any IP Claim of such a third party, and shall not compromise                or settle any IP Claim relating thereto without the prior written                consent                of the other Party, such consent not to be unreasonably withheld                or                delayed.  Ascend shall be responsible for the conduct of the                proceedings in defending any IP Claim, with counsel acceptable to                Columbia.  Ascend shall keep Columbia advised of all material                developments in said proceedings. |
|--------|-------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.4.3     | Ascend                shall indemnify Columbia and its Affiliates against any and all actions,                losses, claims, demands, damages, costs and liabilities (including                reasonable attorneys’ fees) due to any IP Claim, except to the extent that                (i) use of the Columbia Technology as contemplated by this Agreement                necessarily infringes third party patent rights or (ii) the Product                necessarily infringes third party intellectual property rights by                reason                of the Columbia Technology. |
|-------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.4.4     | In                accordance with their obligations pursuant to this Agreement, the                Parties                shall take such action as is reasonable, such as to cease selling                the                Product, or to re-engineer or modify the Product so as to avoid infringing                the patent rights of a |
|-------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

| 3.4.5     | Neither                Party shall have any liability to the other Party whatsoever or howsoever                arising for any losses incurred as a result of Ascend having to cease                selling the Product as a result of an IP                Claim, except that if such an IP                Claim arises due to (i) use of the Columbia Technology as contemplated                by                this Agreement necessarily infringes third party patent rights or                (ii) the                Product necessarily infringes third party intellectual property rights                by                reason of the Columbia Technology, Columbia shall repay to Ascend                the                purchase price of any Product purchased and in Ascend’s then current                inventory that can no longer be sold, including reasonable, documented,                direct, out-of-pocket costs incurred for transportation and/or destruction                of said Product. Columbia shall have no liability to Ascend for any                enhanced or punitive damages awarded as a result of any willful patent                infringement, unless such damages are the direct result of Columbia’s                breach of this Agreement. |
|-------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.5 | Trademarks |
|-----|------------|

| 3.5.1     | Should                the Parties agree to use a trademark other than Prochieve® 4% for the                Product, Columbia shall register the trademark in its name with respect                to                the Product. |
|-------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.5.2     | Columbia                hereby grants to Ascend a non-assignable, non-sublicensable,                non-exclusive, royalty-free right and license to use the Trademark                in the                Territory solely in connection with Ascend’s promotion of the Product in                accordance with this Agreement. Such license shall expire immediately                upon                the expiration or termination of this Agreement. Ascend recognizes                Columbia’s title to the Trademark, and shall not at any time, during or                after the Term, do or knowingly suffer to be done any act or thing                which                will in any way impair the rights of Columbia in or to the                Trademark.  Ascend acknowledges and agrees that it shall not                acquire and shall not claim any title to the Trademark adverse to                Columbia                by virtue of the rights granted under this Agreement or through Ascend’s                use of the Trademark, it being the intention of the parties that                all                goodwill and improved reputation generated by Ascend and use of the                Trademark shall inure to the benefit of                Columbia. |
|-------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

| SECTION                4 - JOINT STEERING COMMITTEE |   |
|-----------------------------------------------------|--------|

| 4.1 | The                Parties recognize that cooperation will be required from each Party                to                successfully commercialize the Product, and for this purpose, the                Parties                will establish a Joint Steering                Committee. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.2 | The                Joint Steering Committee shall consist of a chief representative                from each                Party together with such additional personnel, consultants or                sub-contractors, from each Party who are appropriately skilled and                knowledgeable in relation to the Product. A Party may change any                of its                representatives at any time if a new person (with appropriate expertise                to                replace the outgoing member) is appointed by giving written notice                to the                other Party.  The total number of members may be changed by                unanimous vote of the Joint Steering Committee from time to time                as                appropriate; provided, that the Joint Steering Committee shall in                all                cases be comprised of an equal number of members from each of Columbia                and                Ascend.  One representative from Ascend shall serve as Chairman                of the Joint Steering Committee.  The members appointed to the                Joint Steering Committee by each Party shall be vested with appropriate                decision-making authority and power by such                Party. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.3 | Unless                otherwise agreed by the Parties, the Joint Steering Committee shall                meet                at least once each calendar quarter.  The first meeting of the                Joint Steering Committee shall be held in December 2007.  The                Joint Steering Committee may meet in person or by means of such telephone,                video or other communication facilities as permit all members of                the Joint                Steering Committee to communicate with each other simultaneously                and                instantaneously, provided, however, that the Joint Steering Committee                shall meet at least once per year in person and such meetings shall                be                held at the offices of Columbia, or as otherwise agreed by the                Parties.  Meetings shall be co-chaired by the chief                representatives of the Parties.  Subject to Section 4.4,                decisions shall be made unanimously, each Party having one (1) vote                regardless of the number of representatives present or voting; provided,                that no such vote shall be valid unless each party is represented                by at                least one member either by written proxy or actual presence at the                meeting                at which the vote is taken. At and between meetings of the Joint                Steering                Committee, each Party shall keep the other fully and regularly informed                as                to its progress with its respective                obligations. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.4 | In                the event of a dispute within the Joint Steering Committee that cannot                be                resolved by consensus, such dispute shall be referred to the Presidents                of                Ascend and Columbia who shall discuss the matter and attempt to reach                an                amicable solution.  The provisions of this Section 4.4 shall be                without prejudice to the Parties’ other rights and                remedies. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.5 | The                Joint Steering Committee shall not have the authority to amend, modify                or                waive any of the terms or conditions of this                Agreement. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.6 | The                responsibilities of the Joint Steering Committee shall be exercised                consistent with this Agreement and shall include, but shall not be                limited                to: |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.6.1    | reviewing                and approving the marketing plan prior to the beginning of                each |
|-------------------------|---------------------------------------------------------------------------------------------------------|

----

----

----

|   | calendar                year, including matters relating to managed markets, distribution                and                trade pipeline; |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------|

| 4.6.2                    | monitoring                and reviewing compliance with the marketing plan and, in connection                therewith, reviewing and approving any material change                thereto; |
|-----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.6.3     | reviewing,                coordinating and directing all development activities for the Product,                including matters concerning Product labeling and Phase IV Clinical                Study; |
|-------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.6.4     | reviewing                and approving protocols to be used in any Phase IV Clinical Study                with                respect to the Product; |
|-------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.6.5                    | reviewing                and discussing manufacturing and regulatory status updates provided                by                Columbia to the Joint Steering                Committee; |
|-----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.6.6                    | reviewing                pricing for the Product, including the timing of any pricing changes;                provided that any price increase is subject to Columbia approval                in its                sole discretion and in no event shall the wholesale acquisition cost                for                the Product be less than $38.89 per Finished Dosage Form without                the prior                written consent of Columbia in its sole discretion;                and |
|-----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.6.7                    | such                other functions as may be mutually agreed upon by the parties from                time to                time. |
|-----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|

| 4.7   | For                the avoidance of doubt, any decisions of the Joint Steering Committee                with                respect to matters that require FDA approval or otherwise relate                to                regulatory compliance of the Product shall require Columbia’s prior                written consent. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.8   | The                Joint Steering Committee shall have responsibility for and shall                make all                decisions with respect to any recall, market withdrawal or any other                corrective action related to the Product.  In the interest of                clarity, the power of the Joint Steering Committee with respect to                the                foregoing is limited to (i) the ability to sanction, but not to mandate                a                recall by Ascend, and (ii) vetoing a suggestion by either                Party.  At Ascend’s request and expense, Columbia shall provide                assistance to Ascend in conducting such recall, market withdrawal                or other                corrective action. Columbia shall be under no liability whatsoever                to                compensate Ascend or make any other payment to Ascend for any decision                to                recall, initiate a market withdrawal or take any other corrective                action                with respect to the Product, except in the case of a recall or market                withdrawal caused solely by the negligence or willful malfeasance                of                Columbia, its Affiliates or subcontractors, or by the breach by Columbia                of its representations and warranties in this Agreement, in which                case                Columbia shall replace Product returned and reimburse                Ascend for                its reasonable, documented, direct, out-of-pocket costs in                connection with such recall, market withdrawal or other corrective                action                provided that Ascend shall not be in material breach of its obligations                hereunder and                Columbia’s liability to reimburse Ascend hereunder shall not exceed                [***]. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| SECTION                5 - ASCEND OBLIGATIONS |   |
|-----------------------------------------------|--------|

| 5.1   | Ascend                shall, at its sole expense, warehouse and distribute the Product,                and may                at its sole discretion negotiate and enter into accounts with managed                market entities and institutional customers (e.g., pharmacy benefit                managers, health plans, long term care pharmacy providers, employers,                the                United States Government and state and local governments, including                Medicare), and otherwise ensure that the Product is                freely |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

** **

| 5.2   | Ascend                shall be responsible for: |
|-----------------|-------------------------------------------------|

| 5.2.1   | all                direct and indirect costs incurred by Ascend for its sales force                in                connection with marketing and selling the Product including (without                limitation) sales representative training, sample accountability,                sales                force automation and sales operations                support; |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.2.2   | having                a marketing presence in at least two national-level meetings per                year;                and |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------|

| 5.2.3   | exploring                the possibility of re-branding the Product for gynecological indications                and exploring regulatory options for expanding gynecological indications                for the Product. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.3 | Ascend                shall, at its sole expense, use Commercially Reasonable efforts to                promote                the Product and endeavor to persuade health care professionals to                prescribe, and patients to use, the Product.  All statements,                core selling messages and materials to be utilized by Ascend to promote                the Product shall be subject to the prior approval of Columbia in                accordance with Section 5.8 below.  Ascend will cause its                sales force and Ascend employees and agents acting on Ascend’s behalf to                comply with this Agreement and all applicable legal requirements                in                connection with the promotion of the Product,** **including,                without limitation, the FDA’s regulations and guidelines concerning the                advertising of prescription drug products, DDMAC’s promotional guidelines,                the American Medical Association’s Guidelines on Gifts to Physicians, the                Pharmaceutical Research and Manufacturers of America Guidelines for                Marketing Practices, the Prescription Drug Marketing Act of 1987,                as                amended, and the rules and regulations promulgated thereunder, and                the                Accreditation Council for Continuing Medical Education Standards                for                Commercial Support of Continuing Medical Education, which may be                applicable to the activities (including, without limitation, the                warehousing, handling and distribution of Samples) to be performed                by                Ascend hereunder.  It is understood, and Ascend agrees, that it                will be accountable for the acts or omissions of the sales force                and its                employees and agents to the extent such acts or omissions fail to                comply                with Ascend’s obligations under this                Agreement. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.4   | Ascend                will not make any false or misleading representations to health care                professionals, customers or others regarding Columbia or the Product                and                will not make any representations, warranties or guarantees with                respect                to the specifications, features or capabilities of the Product that                are                not consistent with the applicable current FDA approved labeling,                package                insert or other documentation accompanying or describing the Product,                including Columbia’s limited warranty and disclaimers.  Ascend                shall not make any negative statements about any other Columbia products                in an effort to promote the                Product. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.5 | To                the extent requested by Ascend, Columbia shall deliver to Ascend                all                training materials for the Product in its possession on the date                hereof                less a reasonable amount |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

| 5.6 | Columbia                will have no obligation to train Ascend’s sales force.  Ascend                may request Columbia’s assistance in the initial training and additional                training on new developments in connection with the                Product.  Any such request shall be made with reasonable notice                to Columbia and shall be at Ascend’s expense for Columbia’s out-of-pocket                costs. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.7 | Ascend                shall at its sole expense, create, develop, produce or otherwise                obtain,                and utilize promotional, marketing, educational and training materials                that are necessary to support fully the promotional effort for the                Product.  Such promotional materials may include, by way of                example, detailing aids; leave behind items; journal advertising;                educational programs; formulary binders; appropriate reprints and                reprint                carriers; product monographs; patient support kits; materials to                support                the handling of physician requests; convention exhibit materials;                direct                mail; market research survey and analysis; training materials; and                scripts                for telemarketing and                teleconferences. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.8 | Prior                to the use thereof, Ascend shall provide to Columbia for review prototypes                of all promotional materials created by Ascend.  Columbia shall                notify Ascend of any objections it has to such prototype and the                basis                therefor within thirty (30) days following its receipt                thereof.  Ascend shall modify such promotional materials to the                extent necessary to resolve any objections made by Columbia to such                promotional materials on the grounds that such promotional materials                are                inconsistent with any legal requirements or this Agreement and shall                in                good faith consider and address any of Columbia’s other                objections.  If such promotional materials are approved by                Columbia in accordance with this Section 5.8, Ascend shall provide                Columbia with the requisite number of copies of the final form thereof                in                a timely manner so as to allow Columbia to satisfy its obligation                to file                such materials with DDMAC. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

| 5.9 | To                the extent requested by Ascend, Columbia shall deliver to Ascend                all                promotional materials created by Columbia in its inventory on the                date                hereof less a reasonable amount thereof for archival                purposes.  Columbia shall have no obligation to create                additional copies of any existing promotional materials or to otherwise                incur any expense in connection with providing such existing promotional                materials to Ascend.  Ascend agrees to reimburse Columbia for                any direct costs incurred by Columbia in connection with fulfilling                any                request made by Ascend under this Section 5.9.  Any                existing promotional materials supplied to Ascend under this                Section 5.9 shall be delivered to a single location specified by                Ascend in writing prior to such delivery.  Columbia hereby                grants to Ascend the non-exclusive right, during the Term, to use                any                existing promotional materials supplied to Ascend pursuant to this                Section 5.9 in the performance of its obligations under this                Agreement. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.10 | On                or prior to (a) December 1, 2007, and (b) October 1 of the preceding                calendar year with respect to each calendar year during the Term,                Ascend                shall develop a marketing plan for the calendar year (as applicable),                and                submit the marketing plan to the Joint Steering Committee for review                and                approval.  The marketing plan shall set forth the manner in                which the Product is to be promoted during the period to which the                marketing plan relates. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.11 | The                Parties acknowledge that each may receive requests for medical information                concerning the Product from health care professionals and consumers                regarding the Product.  Until the date six (6) months after the                date hereof or such earlier date as Ascend may specify to Columbia                in                writing, the Parties shall coordinate all professional services activities                through Columbia, who shall be the responsible party for responding                to all                such requests until such time.  Commencing on the date six (6)                months after the date hereof or such earlier date as Ascend may specify                to                Columbia in writing, Ascend shall be responsible for promptly responding                to such requests, which response shall be in compliance with all                applicable legal requirements.  Each Party shall promptly                provide the other Party with (i) copies of all written materials and                (ii) written summaries of all oral advice, provided by such Party in                response to such inquiries.** ** |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.12 | Ascend                shall promptly notify Columbia of any such actions taken by Ascend                that                are reasonably likely to result in a material adverse effect on the                marketability of the Product in the                Territory. |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| SECTION                6 - REGULATORY AFFAIRS |   |
|-----------------------------------------------|--------|

| 6.1 | Columbia                shall be responsible at its expense for maintaining the NDA for the                Product with the FDA, provided, however, that any Phase IV Clinical                Study                will be at Ascend’s sole cost and expense and Ascend will provide to                Columbia any information in Ascend’s possession that Columbia requires to                meet its reporting obligations to FDA.  Ascend agrees that the                NDA and any other submissions to FDA with respect to the Product                shall be                in the name of, and shall be owned by, Columbia or its designee.                Notwithstanding anything to the contrary in this Agreement, should                Columbia determine, in its sole |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

|   | discretion,                that certain information otherwise required to be disclosed to Ascend                and/or to FDA contains trade secrets or proprietary information,                then                Columbia may disclose such information directly to FDA and not to                Ascend,                and Ascend hereby agrees not to seek to obtain such information from                FDA,                or through any other means. |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.2 | Each                Party shall notify the other Party as soon as possible of any notification                received by the Party from FDA or any other regulatory authority                to                conduct an inspection of its manufacturing or other facilities used                in the                development, manufacturing, packaging, storage, or handling of the                Product.  Copies of all material correspondence with the FDA or                other regulatory authority related specifically to the development,                manufacturing, packaging, storage, or handling of the Product will                be                provided by each Party to the other                Party. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.3 | To                the extent Ascend seeks to amend the labeling or support additional                advertising claims for the Product, it may design, conduct and control                such additional Phase IV Clinical Study at its sole expense necessary                to                obtain FDA approval, provided, that Ascend shall give Columbia prior                written notice of its intention to do so. Product and placebo necessary                for the conduct of such Phase IV Clinical Studies shall be supplied                in                bulk by Columbia at Columbia’s fully absorbed cost. Columbia shall own and                have unrestricted rights to the clinical data generated as a result                of                each Phase IV Clinical Study to be filed in connection with Columbia's                regulatory submissions both within and outside the                Territory. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.4 | Unless                otherwise required by law, Columbia will retain exclusive authority                over                and responsibility for complying with all regulatory requirements                and                maintaining all contacts with FDA with respect to the Product, including,                but not limited to, maintaining and updating of the NDA, , the reporting                of any Adverse Drug Reactions to the FDA, the compliance of promotional                materials with FDA rules and regulations, and the filing of promotional                materials with DDMAC, provided however that the submission of applications                to FDA for new indications will be at Ascend’s cost. Ascend shall not,                without the consent of Columbia or unless so required by law, correspond                or communicate with the FDA or with any other governmental authority,                whether within the Territory or otherwise, concerning the Product,                or                otherwise take any action concerning the NDA for the Product or any                application.  Furthermore, Ascend shall, immediately upon                receipt of any communication from the FDA or from any other governmental                authority relating to the Product, forward a copy of the same to                Columbia                and respond to all inquiries by Columbia relating thereto.  If                Ascend is required by law to communicate with the FDA or with any                other                governmental authority relating to the Product, then Ascend shall                so                advise Columbia immediately and provide Columbia in advance with                a copy of                any proposed written communication, or a written summary of any proposed                oral communication with the FDA or any other governmental                authority.  Ascend shall comply with any and all reasonable                direction of Columbia concerning any meeting or written or oral                communication with the FDA or any other governmental authority relating                to                the Product unless otherwise required by                law. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

| 6.5 | Ascend                shall refer any oral or written Product Complaint which it receives                concerning the Product to Columbia within four (4) days of its receipt                thereof; provided, that all complaints concerning suspected or actual                Product tampering, contamination or mix-up shall be delivered within                twenty-four (24) hours of its receipt thereof.  Ascend shall not                take any other action in respect of any such Product Complaint without                the                consent of Columbia unless otherwise required by law.  All                Product Complaints shall be directed to:  Manager, Quality                Assurance, by facsimile at (973)                994 - 3001. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.6 | Each                Party shall notify the other: (i) of all Serious Adverse Drug                Experience Reports within forty-eight (48) hours of the time such                Serious                Adverse Drug Experience Report becomes known to such Party (including                its                employees); and (ii) of all Adverse Drug Experience Reports within                five (5) days of the time such Adverse Drug Experience Report becomes                known to such Party (including its employees). Except as may otherwise                be                required by law, (i) Ascend shall not disclose any information                concerning Adverse Drug Experience Reports or Serious Adverse Drug                Experience Reports to any person or governmental authority without                the                prior consent of Columbia; and (ii) Columbia shall have the sole                discretion to determine whether any Product Complaint, Adverse Drug                Experience Report or Serious Adverse Drug Experience Report must                be                reported to the FDA or any other governmental authority. All follow-up                investigations concerning Adverse Drug Experience Reports and Serious                Adverse Drug Experience Reports shall be conducted by Columbia; provided                that Ascend shall have the right to participate in such investigations                upon its request.  Ascend shall provide all reasonable                cooperation with any such follow-up investigation as may be requested                by                Columbia from time to time. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**SECTION      7 – MANUFACTURING AND      SUPPLY, FORECASTS; PURCHASE ORDERS; MINIMUM PURCHASE      OBLIGATIONS**

| 7.1 | **Ascend                Forecasts** |
|-----|-------------------------------------|

** **

----

----

----

**Binding      Purchase Orders**

**Excess      Quantities; Changes in Purchase Requirements**

**Minimum      Purchase Obligations**

**Manufacturing      Activities**

**Delivery**

----

----

----

| **7.7  ** | **Inspection;                Rejection** |
|---------------------|------------------------------------------|

| 7.8 | Any                Product delivered to Ascend by Columbia which is finally rejected                in                accordance with Section 7.7, or which is otherwise not in compliance                with                the warranties set forth in Section 7.5, shall be replaced at Columbia’s                expense as soon as is Commercially                Reasonable. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Samples**

| 7.9.1   | On                or before                December 15, 2007, Columbia will provide and Ascend will accept                delivery of Samples which will be comprised of [***]. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.9.2   | Columbia                shall provide or cause to be provided to Ascend, from time to time                as                reasonably requested by Ascend, and in such quantities as are mutually                agreed by |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

| 7.9.3   | Ascend                shall be solely responsible for securing the return of and reconciling                Sample inventories from discontinued sales representatives. Upon                its                receipt of Samples, Ascend shall be solely responsible for accountability                and compliance with the PDMA, and other applicable legal requirements                relating to such Samples or the distribution of same and shall be                responsible for adherence by its sales representatives to such legal                requirements.  Columbia shall have the right to audit the                records and/or reports for the Samples, as required to be kept by                Ascend                under the PDMA, during normal business hours, at convenient times                and upon                no less than five (5) calendar days’ prior                notice. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Product**
**Returns**

**SECTION      8 – PRICE AND PAYMENT**

| 8.1   | The                purchase price to be paid by Ascend for the Product in Finished Package                Form shall be thirty-five percent (35%) of the average Net Selling                Price                of the Product per unit in Finished Package Form in the calendar                year                multiplied by the number of units of Finished Package Form delivered                to                Ascend by Columbia. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.2 | Ascend's                initial invoice price for the Product purchased from Columbia shall                be                [***]of the estimated purchase price pursuant to Section 8.1 and                shall be                paid thirty (30) days after the later of (A) receipt by Ascend of                an                invoice for such Product, or (B) the shipment by Columbia of the                corresponding Product. Ascend's payments to Columbia shall be in                U.S.                dollars via wire                transfer of immediately available funds to such bank account as Columbia                shall designate in writing prior to the date of such payment. In                the |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

|   | event                that any payment due under this Agreement is not made when due, the                amount                due shall accrue interest beginning on the tenth (10th) day following                the                date on which such payment was due, calculated at the annual rate                equal to                the higher of one percent (1.0%) per month or two percent (2%) above                the                thirty (30)-day LIBOR for U.S. dollars reported in the *Wall Street                Journal* for the due date, calculated from the due date until paid in                full. Such payment when made shall be accompanied by all interest                so                accrued. |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.3 | Forty-five                (45) days after the end of each calendar year any necessary adjustments                to                such purchase price to reflect the actual thirty-five percent (35%)                of the                average Net Selling Price of the Product per unit in Finished Package                Form                sold in the calendar year multiplied by the number of units of Finished                Package Form delivered to Ascend by Columbia in the calendar year                shall be                made in a report from Ascend to Columbia. Overpayments by Ascend                will be                credited against the next purchase of Product. Underpayments by Ascend                shall be paid to Columbia with the                report. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.4 | Each                Party shall keep full and accurate books, records and invoices with                respect to the its Net Selling Price for no less than three (3) years                after the end of the calendar year during which such sales occurred                during                the Term of this Agreement and for two (2) years                thereafter.  Upon reasonable written notice and not more than                twice in any twelve (12) month period, each Party shall permit an                independent auditor reasonably acceptable to the other Party, to                have                access during normal business hours to sales and payment records                directly                related to sales of the Product in the Territory solely for the purpose                of                determining whether there has been an overpayment or underpayment                by a                Party pursuant to this Agreement for any period ending not more than                twenty-four (24) months prior to the date of such request; provided,                however, that the books and records for any particular period shall                be                subject to only one audit.  Any report rendered by the                independent auditor in connection therewith shall only disclose whether                there has been an overpayment or underpayment and the amount of such                overpayment or underpayment (as the case may be).  The fees and                expenses relating to the services of the independent auditor shall                be                borne by the Party requesting the audit; provided, however, that                the other                Party shall reimburse the Party requesting the audit for the reasonable                fees and expenses of such auditor in the event the audit reveals                an                underpayment for the relevant period of more than five percent                (5%). |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.5 | In                the event that Ascend determines to accept a bona fide offer from                a third                party, or a third party accepts a bona fide offer of Ascend, for                the                Product (i) on or before [***], Ascend agrees to pay Columbia [***],                or                (ii) after [***], but on or before [***], Ascend agrees to pay Columbia                [***].  For the sake of clarity, this provision shall apply only                when the sole asset being transferred is the Product and shall not                apply,                for example, in the event that the Product is transferred to a third                party                due to a merger, acquisition or other form of business                combination. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| SECTION                9 - TERM AND TERMINATION |   |
|-------------------------------------------------|--------|

| 9.1 | This                Agreement shall be deemed to have come into force on the date first                written above and, subject to the rights of termination outlined                in this                Section 9 will expire on the five (5) year anniversary of the Effective                Date (the "Term"). |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

| 9.2 | In                addition to the rights of termination provided for elsewhere in this                Agreement, either Party will be entitled to terminate this Agreement                by                written notice to the other Party                if: |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.2.1   | that                other Party commits any breach of any of the provisions of this Agreement,                and in the case of a breach capable of remedy, fails to remedy the                same                within sixty (60) days after receipt of a written notice of the breach                and                requiring it to be remedied or within ten (10) days in the case of                a                failure to make a monetary payment;                or |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.2.2   | if                that other Party shall make a general assignment for the benefit                of                creditors, or files or has filed against it a petition for                bankruptcy, reorganization or an arrangement for the benefit of creditors,                or for the appointment of a receiver, trustee or creditor representative                for the property or assets of such Party under any federal or state                insolvency law, which, if filed against such Party, has not been                dismissed                or discharged within sixty (60)                days. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.3 | For                the purposes of Section 9.2.1, a breach will be considered capable                of                remedy if the Party in breach can comply with the provision in question                in                all respects other than as to the time of performance (provided that                time                of performance is not of the                essence). |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.4 | Ascend                may terminate this Agreement upon not less than sixty (60) days prior                written notice to Columbia if: |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------|

| 9.4.2   | A                product recall or market withdrawal occurs that is material to the                reputation or ongoing supply of the product and not the result of                the                negligence or misconduct of Ascend. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.5   | Ascend                may terminate this Agreement without cause for any reason upon not                less                than one hundred eighty (180) days prior written notice to Columbia;                provided, however, that: Ascend shall not be due any Sunset                Fee. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.6   | Columbia                may terminate this Agreement upon written notice to Ascend in the                event                that (i) the number of units of Product dispensed to patients foruses                relating                to fertility, pregnancy, and preterm birth in any calendar quarter,                as determined by data from the IMS Health National Drug and Therapeutic                Index, equals or exceeds [***]of                Product dispensed for all uses in such calendar quarter, (ii) Columbia                notifies Ascend in writing of Columbia’s intent to terminate this                Agreement under this Section 9.6, and (iii) the number of units of                Product                dispensed to patients for uses                relating                to fertility, pregnancy, and preterm birth equals or exceeds [***]of  Product                dispensed to patients for all                uses                during the three full calendar month period immediately following                receipt of such notice (the "Cure Period"); provided, however, that                Columbia may immediately terminate this Agreement at any time after                the                Cure Period upon written notice to Ascend in the event that the number                of                units of Product dispensed to patients for uses                relating                to fertility, pregnancy, and preterm birth in any three-month                period after the Cure Period (and not |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

| 9.7   | Ascend                may terminate this Agreement upon written notice to Columbia in the                event                that (i) the number of units of Crinone and Prochieve 8% dispensed                to                patients for uses                relating                to the Indication in any calendar quarter, as determined by data                from the IMS Health National Drug and Therapeutic Index, equals or                exceeds                [***]of                Product dispensed for all uses in such calendar quarter, (ii) Ascend                notifies Columbia in writing of Ascend’s intent to terminate this                Agreement under this Section 9.7, and (iii) the number of units of                Crinone                and Prochieve 8% dispensed to patients for uses                relating                to the Indication equals or exceeds [***]of  Product                dispensed to patients for all                uses                during the Cure Period; provided, however, that Ascend may                immediately terminate this Agreement at any time after the Cure Period                upon written notice to Columbia in the event that the number of units                of                Crinone and Prochieve 8% dispensed to patients for uses                relating                to the Indication in any three-month period after the Cure Period                (and not including any month during the Cure Period) equals or exceeds                [***]of                Product dispensed to patients for all uses                in such three-month period. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| SECTION                10 - CONSEQUENCES OF TERMINATION |   |
|---------------------------------------------------------|--------|

| 10.1 | Upon                exercise of those rights of termination specified in Section 9 or                elsewhere in this Agreement, this Agreement shall, subject to the                provisions of this Agreement which survive the termination of this                Agreement, terminate and be of no further legal force or                effect. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.2 | Termination                of this Agreement by Columbia or by Ascend shall be without prejudice                to                Columbia’s right to receive payment of all obligations owed to, and costs                incurred by, Columbia during the period prior to the effective date                of the                termination.  Ascend shall be liable to Columbia for any                uncancellable obligations and expenses incurred by Columbia prior                to such                termination in connection with the Product and all costs incurred                by                Columbia in terminating such work. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.3 | Upon                termination of the Agreement by either Party, the following shall                be the                consequences: |
|------|------------------------------------------------------------------------------------------------------------------------------------------|

| 10.3.1   | all                confidentiality provisions set out herein shall remain in full force                and                effect for a period of 10** **years from the date of                termination of this Agreement; |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.3.2                   | all                responsibilities and warranties shall insofar as appropriate remain                in                full force and effect, including without limitation the provisions                of                Sections 3 (Intellectual Property) and 11 (Warranty and Indemnity),                which                shall survive any termination of this                Agreement; |
|------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.3.3                   | the                rights of inspection and audit shall continue in force for the period                referred to in the relevant provisions of this                Agreement; |
|------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

| 10.3.4   | Columbia                shall be entitled to research, develop and commercialize the Product                for                its own benefit in the Territory in accordance with the provisions                of                Section 10.4; and |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.3.5   | Ascend                shall deliver to Columbia all training and promotional materials                created                by Ascend in its inventory on the termination date less a reasonable                amount thereof for archival                purposes. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.4   | Following                (i) the Term (or any extension thereof), (ii) the early termination                of                this Agreement without cause by Columbia, or (iii) the early termination                of this Agreement without cause by Ascend which termination is on                or after                January 1, 2010, Columbia shall pay to Ascend a “Sunset Fee” consisting of                [***]of                Columbia’s “Net Sales” (determined by multiplying Columbia’s                average Net                Selling Price during the period by the number of units sold by Columbia                during the period) over [***]                in the first full year after termination, and [***]of                Columbia’s Net Sales over [***]                in the second full year after                termination. |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.5 | Upon                the termination of this Agreement for any reason, each Party shall                return                the other Party’s Confidential Information to such other Party or at the                other Party’s option, destroy all originals and copies of the other                Party’s Confidential Information; provided, that each Party may retain                a                copy of the other Party’s Confidential Information in its legal department                for archival purposes. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 10.6 | If                this Agreement is terminated by Columbia for cause pursuant to Section                9,                Ascend shall discontinue use of the Product and shall arrange, at                Ascend’s                sole cost and expense, for the lawful disposal of all unsold                Product.  In the event of any other termination or expiration of                this Agreement, Ascend shall be entitled to retain, use and sell                any                remaining supplies of Product then in its possession or control,                provided                that any such use or sale shall be subject to the terms and restrictions                of this Agreement and Columbia shall not take any action to impair                such                use or sale by Ascend; |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.7 | If                Columbia should require for any reason whatsoever a license from                Ascend in                order to research, develop and commercialize the Product after the Term or                earlier termination of this Agreement, Ascend hereby grants to Columbia                a                non-exclusive, fully paid, royalty free license, with the right to                sublicense, for the purposes of making, having made, packaging, importing,                using, offering for sale, selling and having sold the                Product. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**SECTION      11 - WARRANTY AND INDEMNITY**

| 11.1.1   | it** **is                a corporation duly organized, validly existing and in good standing                under                the laws of the state of its incorporation, and it has all necessary                corporate power and corporate authority to own its properties and                to                conduct its business, as currently                conducted; |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

| 11.1.2   | the                execution and delivery of this Agreement and the consummation of                the                transactions contemplated hereby are within its corporate power,                have been                duly authorized by all necessary corporate proceedings, and this                Agreement                has been duly executed and delivered by                it; |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.1.3   | the                execution and delivery of this Agreement and the consummation of                the                transactions contemplated hereby do not: conflict with or result                in a                breach of any provision of its organizational documents; result in a                material breach of any material agreement to which it is                party; require it to obtain any material approval or                consent  from any governmental authority or third party other                than those consents and approvals which have been obtained prior                to the                date hereof; or violate any legal requirement applicable to it in any                material respect; |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.1.4   | this                Agreement                constitutes a valid and binding obligation, enforceable against it                in                accordance with its terms, subject to bankruptcy, reorganization,                insolvency and other similar laws affecting the enforcement of creditors’                rights in general and to general principles of equity (regardless                of                whether considered in a proceeding in equity or an action at law);                and |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.1.5   | in                performing a Phase IV Clinical Study, it will exercise all due skill                and                care in conducting such activities; and it will comply with the provisions                of this Agreement, all FDA and other approvals, all applicable state                and                local regulatory approvals and all applicable laws, ordinances and                regulations. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2   | Columbia                warrants and represents to Ascend                that: |
|------------------|--------------------------------------------------------------------------------|

| 11.2.1                   | to                the knowledge of Columbia as of the date hereof, (i) the manufacture,                use,                importation, promotion and sale of the Product in the Territory in                accordance with this Agreement will not infringe any patents, trademarks                or other intellectual property rights of any third party, (ii) none                of the                Patents are invalid, (iii) the Patents are in full force and are                not                subject to any pending, or to the knowledge of Columbia as of the                date                hereof, threatened re-examination, opposition, interference or litigation                proceedings in the Territory; |
|------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 11.2.2    | to                the knowledge of                Columbia as of the date hereof there is approximately one month of                inventory of the Product in the                trade; |
|--------|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 11.2.3                   | Columbia                has not and will not during the Term acquire another product that                competes                directly with the Product, provided that, for the avoidance of doubt,                the                8% w/w progesterone gel (90 mg) in single use, one piece, disposable                vaginal applicators containing 1.45 g of gel and delivering 1.125                g of                gel, utilizing the Columbia Technology, and approved by the FDA under                NDA                20-701, and any comparable product in a progressive hydration vaginal                tablet, are not competitive                products; |
|--------|------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

|   | 11.2.4    | Columbia                has not and during the Term will not enter into any contracts with                government entities concerning the Product that require reimbursements                under Medicaid, Medicare or other government payer                programs; |
|--------|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 11.2.5    | as                of the date                hereof there are no pending or threatened Claims or IP Claims                related to the Product; and |
|--------|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 11.2.6    | as                of the date                hereof the Product is safe and effective for use as it is currently                labeled and sold. |
|--------|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|

| **11.3  ** | **Indemnification                by Columbia** |
|----------------------|------------------------------------------------|

| **11.4  ** | **Indemnification                by Ascend** |
|----------------------|----------------------------------------------|

| **11.5  ** | **Cooperation**  The                Parties agree that: |
|----------------------|-------------------------------------------------------------------|

| 11.5.1    | the                indemnifying Party shall have the right in its sole discretion to                conduct                all proceedings and negotiations connected with such Claims; provided,                however, that the indemnifying Party shall not settle any Claim without                the consent of the indemnified Party, which consent shall not be                unreasonably withheld or delayed; and provided, further, that if                the                indemnifying Party fails to defend a Claim, the indemnified Party                shall                have the right to undertake the defense of any such                Claim |
|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

|   | at                the expense and for the account of the indemnifying Party and the                indemnifying Party shall pay all such expenses within thirty (30)                days of                the receipt of any invoice with respect                thereto; |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.5.2                   | the                indemnified Party shall promptly notify the indemnifying Party of                all such                Claims and shall not make any admissions regarding them unless legally                required to do so; |
|------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.5.3    | the                indemnified Party shall, at the indemnifying Party’s expense, provide the                indemnifying Party with reasonable assistance in connection with                such                claims; |
|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.5.4    | the                indemnifying Party** **shall keep the indemnified                Party** **informed as to the status of any Claim, and                not less than every sixty (60) days shall provide the indemnified                Party** **with a written status report on the                Claim. |
|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.6 | THE                WARRANTIES CONTAINED IN THIS SECTION 11 ARE IN LIEU OF ALL OTHER                REPRESENTATIONS AND WARRANTIES.  COLUMBIA DISCLAIMS ALL OTHER                WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ALL                WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT, EXCEPT AS OTHERWISE                PROVIDED HEREIN, OR FITNESS FOR A PARTICULAR PURPOSE.  EXCEPT AS                EXPRESSLY STATED IN SECTION 7 AND THIS SECTION 11, COLUMBIA SHALL                NOT BE                LIABLE IN CONTRACT, TORT OR OTHERWISE FOR ANY LOSS, DAMAGE, EXPENSE                OR                INJURY, ARISING OUT OF OR IN CONNECTION WITH A PRODUCT OR ANY DEFECT                IN A                PRODUCT OR FROM ANY OTHER CAUSE. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.7 | NOTWITHSTANDING                ANYTHING TO THE CONTRARY IN THIS AGREEMENT, COLUMBIA AND                ASCEND  SHALL NOT BE LIABLE TO THE OTHER BY REASON OF ANY                CONDITION OR TERM OR DUTY OF COMMON LAW, OR UNDER THE EXPRESS TERMS,                REPRESENTATIONS OR WARRANTIES OF THIS AGREEMENT, FOR ANY CONSEQUENTIAL,                SPECIAL OR INCIDENTAL OR PUNITIVE LOSS OR DAMAGE (WHETHER FOR LOSS                OF                CURRENT OR FUTURE PROFITS, LOSS OF ENTERPRISE VALUE OR OTHERWISE)                AND                WHETHER OCCASIONED BY THE NEGLIGENCE OF THE RESPECTIVE PARTIES, THEIR                EMPLOYEES OR AGENTS OR OTHERWISE.  EXCEPT AS OTHERWISE EXPRESSLY                STATED IN THIS AGREEMENT, WITH RESPECT TO ANY CLAIM OF DAMAGES,                COMPENSATION OR MONETARY RECOVERY OR OTHER RELIEF ASSERTED OR WHICH                CAN BE                ASSERTED BY ASCEND , IN NO EVENT SHALL ASCEND  MAKE ANY CLAIM,                BE PERMITTED TO RECOVER, SEEK TO OBTAIN OR OBTAIN, ENCOURAGE OR ASSIST                OR                PERMIT ANY THIRD PARTY TO OBTAIN, ANY AWARD OF DAMAGES, FINDING OF                LIABILITY OR ANY EQUIVALENT THERETO, REGARDLESS OF THE FORM OF SUCH                ACTION, WHETHER IN CONTRACT OR TORT, OR AT LAW OR EQUITY AND WHETHER                PERMITTED UPON FRAUD, MISREPRESENTATION OR OTHERWISE, AGAINST COLUMBIA,                ITS SHAREHOLDERS, AFFILIATES, SUBSIDIARIES, AGENTS,                EMPLOYEES, |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

|   | DIRECTORS,                OFFICERS AND/OR ANY PERSON OR ENTITY ACTING IN CONCERT OR UNDER THE                DIRECTION OF COLUMBIA, IN AN AMOUNT WHICH WOULD RESULT IN A PAYMENT                TO                ASCEND  OR ANY OTHER PERSON OR ENTITY WHICH EXCEEDS THE TOTAL                AMOUNTS ACTUALLY PAID TO COLUMBIA BY ASCEND  UNDER SECTION 8 OF                THIS AGREEMENT DURING THE TWELVE (12) MONTHS IMMEDIATELY PRECEDING                THE                DATE SUCH CLAIM OF LIABILITY IS MADE.  ASCEND AGREES TO ENTER                INTO SUCH STIPULATIONS OF FACT OR LAW AS MAY BE REQUIRED TO GIVE                EFFECT TO                THIS PROVISION. |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.8 | **Insurance:** |
|------|----------------|

| 11.8.1   | At                all times while this Agreement is in effect, each Party shall procure                and                maintain, at its own expense and for its own benefit, the following                insurance in amounts no less than that specified for each                type: |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.8.1.1    | commercial                general liability insurance with combined limits of                **[***]**per occurrence, **[***]**per accident                for bodily injury, including death, and property damage, which policy                shall include coverage for all hired, owned and not-owned automobiles                and                trucks; |
|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.8.1.2    | worker’s                compensation and disability insurance in the amount required by the                law of                the state in which such party’s employees are located and employer’s                liability insurance with limits of **[***]**per                occurrence; |
|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.8.1.3    | automobile                liability insurance covering automobiles and trucks used by or on                behalf                of such party with combined single limit of **[***]**per                occurrence and **[***]**per accident for bodily injury,                including death, and property damage, which policy shall include                coverage                for all hired, owned and not-owned automobiles and trucks;                and |
|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.8.1.4    | product                liability insurance with limits of not less than **[***]**per                occurrence and in the aggregate. |
|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------|

|   |   | 11.8.2   | Upon                request, no more often than on an annual basis, a Party shall furnish                the                other Party with a certificate(s) from the insurance carrier(s) (having                a                minimum AM Best rating of A) showing the coverages set forth above                and                naming the other Party an additional insured.  This insurance                may be cancelled or altered only after thirty (30) days written notice                is                given to the other Party. |
|--------|--------|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**SECTION      12 - MISCELLANEOUS PROVISIONS**

**Confidentiality**

| 12.1.1    | Any                information, whether written or oral, pertaining to the Product or                the                commercialization thereof that has been or will be communicated or                delivered by Columbia to Ascend, or by Ascend to Columbia, including,                without limitation, |
|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

|   | trade                secrets, business methods, and cost, supplier, manufacturing and                customer                information, shall be treated by Ascend and Columbia, respectively,                as                Confidential Information, and shall not be disclosed or revealed                to any                third party whatsoever or used in any manner except as expressly                provided                for herein; provided, however, that such Confidential Information                shall                not be subject to the restrictions and prohibitions set forth herein                to                the extent that such Confidential                Information: |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.1.1.1     | is                available to the public in public literature or otherwise, or after                disclosure by one Party to the other becomes publicknowledge through                no                fault** **of the Party receiving such Confidential                Information; or |
|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.1.1.2    | was                known to the Party receiving such Confidential Information prior                to the                receipt of such Confidential Information by such Party, whether received                before or after the date of this Agreement;                or |
|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.1.1.3    | is                obtained by the Party  receiving such Confidential Information                from a third party not subject to a requirement of confidentiality                with                respect to such Confidential Information;                or |
|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.1.1.4    | is                required to be disclosed pursuant to: (i) any order of a court having                jurisdiction and power to order such information to be released or                made                public; or (ii) any lawful action of a governmental or regulatory                agency                provided that each Party  shall notify the other in writing of                any disclosure of information required hereunder prior to such                disclosure. |
|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.1.2                   | Each                Party  shall take in relation to the Confidential Information of                the other Party  all such precautions as it normally takes with                its own Confidential Information to prevent any improper disclosure                of                such Confidential Information to any third party; provided, however,                that                such Confidential Information may be disclosed within the limits                required                to obtain any authorization from the FDA or any governmental or regulatory                agency or, with the prior written consent of the other Party, which                shall                not be unreasonably withheld or delayed, or as may otherwise be required                in connection with the purposes of this                Agreement. |
|------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.1.3    | Each                of the Parties agrees that it will not use, directly or indirectly,                any                know-how of the other Party (including Columbia Know-How), or other                Confidential Information disclosed to it by the other Party or obtained                by                it from the other Party  pursuant to this Agreement, other than                as expressly provided herein. |
|--------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.1.4    | Neither                Party will publicize the existence of this Agreement in any way without                the prior written consent of the other Party subject to the disclosure                requirements of applicable laws and regulations.  In the event                that either Party wishes to make an announcement concerning the Agreement,                that Party will seek the consent of the other Party.  The terms                of any such announcement shall be agreed in good                faith.  Columbia and Ascend shall also co-operate in good faith                with respect to |
|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

|   | any                stock exchange filings, public announcements, or filings with the                United                States Securities and Exchange Commission that may be necessary following                execution of this Agreement. |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **12.2  ** | **Alternative                Dispute Resolution** |
|----------------------|---------------------------------------------------|

| 12.2.1                  ** ** | The                Parties will try to settle their differences amicably between                themselves.  If any claim, dispute, or controversy of whatever                nature arising out of or relating to this Agreement, including the                performance or alleged non-performance of a Party of its obligations                under                this Agreement arises between the Parties (each a “Dispute”), a Party may                notify the other Party in writing of such Dispute.  If the                Parties are unable to resolve the Dispute within 20 days of receipt                of the                written notice by the other Party, such Dispute will be referred                to the                Chief Executive Officers of each of the Parties who will use their                good                faith efforts to resolve the Dispute within 30 days after such                referral. |
|----------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.2.2     | If                a Dispute is not resolved as provided in the preceding Section 12.2.1,                whether before or after termination of this Agreement, the Parties                hereby                agree to resolve such Dispute by final and binding arbitration                administered under the rules of arbitration of the American Arbitration                Association (AAA) (the “Rules”) by one arbitrator appointed in accordance                with the Rules, provided that upon request of either Party, three                arbitrators will be appointed, thus forming a panel.  If the                Parties are unable to mutually select such panel within 30 days after                initiating such selection procedure, the panel will be selected in                accordance with the Rules as applicable to a panel of three                arbitrators.  The decision and award rendered by the panel will                contain findings of fact and conclusions of law and be final and                binding.  In any such arbitration, the arbitrators will not have                the right to modify the terms and conditions of this                Agreement.  As a result, the rights and obligations of the                Parties will be determined in accordance with the terms and conditions                of                this Agreement and any decision or award will be only in accordance                with                the terms and conditions of this Agreement.  The Parties will                exert reasonable efforts to have the decision and award rendered                within                six (6) months after the first to occur of (i) notice of breach of                this                Agreement, which breach is a subject of the arbitration, and (ii)                a notice                invoking this arbitration provision.  Judgment upon the award                may be entered in any court having jurisdiction thereof.  Any                arbitration pursuant to this section will be held in Wilmington,                Delaware,                or such other place as may be mutually agreed upon in writing by                the                Parties.  With respect to any Disputes arising in connection                with an alleged breach of a Party’s rights and obligations with respect to                confidential Know-How or Confidential Information received from the                other                Party, the arbitrator will apply the discovery provisions of the                Federal                Rules of Civil Procedure.  This means that depositions may be                taken and full discovery may be obtained in any arbitration commenced                under this Section with respect to such                Disputes. |
|--------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.2.3     | Notwithstanding                the provisions of this Section, either Party will have the right                to |
|--------------------------------|-------------------------------------------------------------------------------------------------------------------|

----

----

----

| 12.3** ** | Assignments/Sub-contracting |
|----------------|-----------------------------|

| 12.4 | **Severability** |
|------|------------------|

| 12.4.1    | such                provision will be deemed amended to conform to applicable laws so                as to be                valid and enforceable or, if it cannot be so amended without materially                altering the intention of the Parties, it will be deleted, with effect                from the date of such agreement or such earlier date as the Parties                may                agree; and |
|--------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.4.2    | the                validity, legality and enforceability of the remaining provisions                of this                Agreement shall not be impaired or affected in any                way. |
|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.5 | **Force                Majeure** |
|------|----------------------------------|

----

----

----

| 12.6 | **Relationship                of the Parties** |
|------|------------------------------------------------|

**No      Third-Party Rights**

**Entire      Agreement**

**Interpretation**

----

----

----

| 12.10 | **Public                Statements** |
|-------|--------------------------------------|

| 12.11 | **Amendments** |
|-------|----------------|

| 12.12 | **Waiver** |
|-------|------------|

| 12.13 | **No                Effect on Other                Agreements** |
|-------|-----------------------------------------------------------------|

| 12.14 | **Governing                Law and Jurisdiction** |
|-------|---------------------------------------------------|

| 12.15 | **Counterparts** |
|-------|------------------|

| 12.16 | **Notice** |
|-------|------------|

----

----

----

----

----

----

----

----

----

----